Browsing Tag

HUTCHMED

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with…

James Pereira Jul 20, 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

James Pereira Jul 10, 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

James Pereira Apr 12, 2023

<!--…
Read More...

James Pereira Mar 31, 2023

<!--…
Read More...

James Pereira Jan 3, 2023

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

James Pereira Dec 19, 2022

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and…
Read More...

James Pereira Nov 14, 2022

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in…
Read More...

James Pereira Oct 10, 2022

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

James Pereira Aug 9, 2022

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals…
Read More...

James Pereira Aug 8, 2022

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy…
Read More...